How a novel pediatric gene therapy developer leveraged regulatory gap analysis to align with FDA expectations By Tom Hallam, Ph.D., MBA For emerging pharmaceutical companies navigating the road to U.S. market approval, the righ...

How a novel pediatric gene therapy developer leveraged regulatory gap analysis to align with FDA expectations By Tom Hallam, Ph.D., MBA For emerging pharmaceutical companies navigating the road to U.S. market approval, the righ...

By Lisa Jenkins VanLuvanee, Ph.D. I hear all the time from life sciences CEOs and innovators, “I don’t know what I don’t know, and that keeps me up at night.” One of the best ways to address this situation is to obtain a gap an...

gET sOCIAL